Coherus BioSciences Inc. (CHRS)
| Bid | 0.82 |
| Market Cap | 97.67M |
| Revenue (ttm) | 268.07M |
| Net Income (ttm) | 28.63M |
| EPS (ttm) | 0.25 |
| PE Ratio (ttm) | 3.37 |
| Forward PE | -77.73 |
| Analyst | Buy |
| Ask | 0.94 |
| Volume | 1,200,323 |
| Avg. Volume (20D) | 2,013,826.5 |
| Open | 0.86 |
| Previous Close | 0.85 |
| Day's Range | 0.83 - 0.89 |
| 52-Week Range | 0.66 - 2.61 |
| Beta | 0.93 |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...
Analyst Forecast
According to 4 analyst ratings, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 730.66% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call TranscriptCoherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaok...